Reflecting real-world patients with mesothelioma in research: an interim report of baseline characteristics from the ASSESS-meso cohort
-
Published:2023-11
Issue:6
Volume:9
Page:00467-2023
-
ISSN:2312-0541
-
Container-title:ERJ Open Research
-
language:en
-
Short-container-title:ERJ Open Res
Author:
Conway Ruairi J.H., Smith NatalieORCID, Cooper William, Lynch GeraldineORCID, Patole Sonia, Symonds Jenny, Edey Anthony, Maskell Nick A., Bibby Anna C., Zahan-Evans Natalie, Tucker Emma, Stadon Louise, Maskell Nick, Harvey John, Day Helen, Rahman Najib, Fallon Janet, Redwood Dawn, Wainwright Tania, Morgan Sarah, Darlison Liz, Walter James, Masani Vidan, Corcoran John, Dixon Mairead, Slaven Kate, Aujayeb Avinash, Taylor Leah, Dismore Lorell, Brown Louise, Beckett Paul, Blyth Kevin, Tsim Selina, Maclay John, Macpherson Alexandra, Cox Giles, Shaw Paul, Chamberlin Naomi, Lawson Malcolm, Mukherjee Dipak, Dancey Gairin, Islam Rafiqul, Mishra Eleanor, Pope Tony, Steer Henry, Bintcliffe Oliver, de Fonseka Duneesha,
Abstract
ObjectiveMesothelioma varies in clinical phenotype and survival. Clinical trials are unavoidably affected by selection bias, reducing generalisability. ASSESS-meso is a UK, multicentre, prospective, mesothelioma cohort study (ISRCTN61861764). This pre-specified interim analysis, conducted when recruitment reached 25% of target, summarised participant characteristics and evaluated external validity through comparison with real-world and clinical trial cohorts.MethodsThe study took place at 14 hospitals across the UK. People diagnosed with mesothelioma, at any anatomical site, were eligible. Clinical, radiological and biochemical data were collected at enrolment. In this interim report, the external validity of the cohort was investigated through comparison of baseline demographic data with populations included in the 2020 UK National Mesothelioma Audit (real-world cohort), and CHECKMATE-743 and MAPS trials (clinical trial cohorts).Results244 patients were enrolled between 7 April 2017 and 1 March 2022. The cohort was predominantly male (195 out of 244; 80%) with a median age of 74 years. Pleural disease and epithelioid subtypes were most prevalent. ASSESS-meso participants were more similar to the real-world population with regard to age, performance status, disease site and stage than the clinical trial population. ASSESS-meso participants were more likely to be formally staged and less likely to have undifferentiated histology compared with the real-world cohort, possibly reflecting high rates of discussion of ASSESS-meso participants at regional mesothelioma multidisciplinary team meetings. As expected, poorer performance status, non-epithelioid histology and neutrophil–lymphocyte ratio were associated with shorter survival in the adjusted analysis.ConclusionASSESS-meso is representative of the UK mesothelioma population. Future outputs from the cohort will help characterise different mesothelioma phenotypes with high external validity.
Funder
Cancer Research UK Avon Mesothelioma Foundation
Publisher
European Respiratory Society (ERS)
Subject
Pulmonary and Respiratory Medicine
|
|